Trevi Therapeutics (TRVI) Misses Q3 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Ladybug Resource Group updates M&A program, holds early financing talks
• General Mills (GIS) Tops Q1 EPS by 3c
• 2G Energy receives 275 MW order from Energy Vault for U.S. data centers